April 30, 2021 -- Biotech company Capricor Therapeutics announced it has signed an exclusive worldwide licensing agreement with Johns Hopkins University to include engineered exosomes for vaccines and therapeutics in its exosome technology portfolio.
The agreement will enable Capricor to exclusively develop, manufacture, and commercialize intellectual property related to exosome technology for applications across both vaccine and therapeutic areas, with the right to sublicense. The licensed technology is based on research conducted in partnership with Stephen Gould, PhD, a Capricor executive consultant and professor of biological chemistry at Johns Hopkins.
The ease with which exomes cross cell membranes and their ability to communicate in native cellular language makes them a promising class of novel therapeutic agents, according to the company.
Copyright © 2021 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
